Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KCSG-TRIUMPH Umbrella Trial in HNSCC
NCT03292250Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2017
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib, poziotinib, nintedanib, abemaciclib, durvalumab and 1 more in head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by Seoul National University Hospital. Primary endpoints: Disease Control Rate at 24 months and Response Rate at 24 months. Started Sep 2017; status: completed.
02
Drugs
alpelisibpoziotinibnintedanibabemaciclibdurvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03292250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292250.